{"id":786918,"date":"2023-09-28T17:22:37","date_gmt":"2023-09-28T21:22:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\/"},"modified":"2023-09-28T17:22:37","modified_gmt":"2023-09-28T21:22:37","slug":"exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\/","title":{"rendered":"Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, California, Sept.  28, 2023  (GLOBE NEWSWIRE) &#8212; Exagen Inc.\u00a0(Nasdaq: XGN),\u00a0a leading provider of autoimmune testing solutions, announced today the acceptance of five abstracts at the 2023 American College of Rheumatology\u2019s (ACR) annual meeting, ACR Convergence 2023, being held November 10-15, 2023, at the San Diego Convention Center in San Diego, California.<\/p>\n<p>Below is the list of accepted abstracts, with links to each:<\/p>\n<p>\n        <strong>Sunday, November 12, 2023<\/strong>\n      <\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fPb163CU5CPbBeO4GgDhM-vZiU6VjW6f3zRmCKQtSIDa1zSHSDPIVKQ78_ezqmfLtGvxgmFdj3sYn56D1GrMD_lTAoj4v0viig-t76uMw7D90LyW_zWI-Syk2vpDfa10QJf76F4RYTXinM_4uBwXDo2cdcdgxYoHH7pc7r1uG9MvKGbTZ4l5sRdtax-QCVVZDFAi-ueRlj8-NtsqMjnnQGPFAzDk1o5uTbXINFPIRnOCqUG5VI8tmL-H6OyAHogZ2ErJnkm7WcsQ4216TMxBZx2SQFaVd_5qJ1TevaPzlacyxgOVncIZAfgFgqycB35MZjFxKJKbp6ReJ70UkA1FYOVrkAvO64KNngn4IPK6KnA=\" rel=\"nofollow noopener\" target=\"_blank\">Poster Presentation | Presented by Doruk Erkan | Abstract #0099<\/a><br \/>\n        <br \/>Title: Cell-bound Complement Activation Products in Antiphospholipid Antibody-positive Patients Without Other Systemic Autoimmune Diseases<br \/><em>Session Title:<\/em> Poster Session A<br \/><em>Session Time:<\/em> 9:00 \u2013 11:00am PT<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fPb163CU5CPbBeO4GgDhM-vZiU6VjW6f3zRmCKQtSIDa1zSHSDPIVKQ78_ezqmfLO_HsVPa1lxNAVqVrtJczwWb0oZxRx0WtFPE-35BxlBzi5rBJHpMYgpsO76jI_m7DaaGvojgu8dq9kZrhyyeFftqOQ-_kEEskf0SXOllJLHa94RsbdAEGKbZUakI3S9fP_wnCRJng8YuzDRsAfY92vjvH-DzTHLvrLBch1xvBufnKZiiMidSJCljT_K-Ns_CzvNDjdEiZxKUCAZ3fdcM0lurjlc4NIFTOv0iTincKNJHuU0IQYKunpeV5CVgqTTtD\" rel=\"nofollow noopener\" target=\"_blank\">Poster Presentation | Presented by Jennifer Rogers | Abstract #0557<\/a><br \/>\n        <br \/>Title: Longitudinal Evaluation of Cell-bound Complement Activation Products in Patients with SLE<br \/><em>Session Title:<\/em> Poster Session A<br \/><em>Session Time:<\/em> 9:00 \u2013 11:00am PT<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fPb163CU5CPbBeO4GgDhM-vZiU6VjW6f3zRmCKQtSIDa1zSHSDPIVKQ78_ezqmfLhVylb0475b0g7C35m4bJk30NtY07CF04guYXuJncNckSsQurU_3QBT0P3WlscbadKNaGdBd0kiVEqsUKWUTqNbb_EqiPdzP7GPiNjtebNQeryR4FHQatRLvOFnwIlg3VE1uOwjv_pamxE5la0PO_CqTv3ow5n9zN90EuEtA2IDO8kozmt2SpScKHgIXAftZZEuiyCaV0hjn2pxzabvvSXGo6SAngiGmWV_68enk5KehOrUfTMvmekHO56qZz5aBWCS6AuBhXcJ0B4_6J5sjJwQ==\" rel=\"nofollow noopener\" target=\"_blank\">Poster Presentation | Presented by Andrew Concoff| Abstract #0575<\/a><br \/>\n        <br \/>Title: The Real-World Utility of a Lupus Activity Monitoring Panel in the United States Community Rheumatologist Practice<br \/><em>Session Title:<\/em> Poster Session A<br \/><em>Session Time:<\/em> 9:00 \u2013 11:00am PT<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fPb163CU5CPbBeO4GgDhM-vZiU6VjW6f3zRmCKQtSIDa1zSHSDPIVKQ78_ezqmfLhVylb0475b0g7C35m4bJk30NtY07CF04guYXuJncNcl05z4pR91VPk7zKjw7MdrVH46-L0LOxFWymGdTvIeOD6cWGrpVY2wRTyfxOV3TB8HOClyo2pkoksz54jhUSnmH3fRos0DHK0LKYupWQf_e5Y_2VTuzec5eladrXJjqnDgjFxUR-trs34lXJCMyWHYkBc4JWhBsoI5-9CWmGHS1aepnkeVJPnDWED1K_33Gj7V-odKAVoR0QqffunsV3KFX_DPRASHE2kV5jZKd55NrqDU8NThozGVDlpLPDwlPMrDIhhpisAiKPJXnhnKl4lFK\" rel=\"nofollow noopener\" target=\"_blank\">Poster Presentation | Presented by Andrew Concoff| Abstract #0576<\/a><br \/>\n        <br \/>Title: Enhancing Systemic Lupus Erythematosus Diagnosis: Comparative Performance Characteristics of TC4d and Anti-T-Cell Antibodies with Conventional Biomarkers<br \/><em>Session Title:<\/em> Poster Session A<br \/><em>Session Time:<\/em> 9:00 \u2013 11:00am PT<\/p>\n<p>\n        <strong>Tuesday, November 14, 2023<\/strong>\n      <\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fPb163CU5CPbBeO4GgDhM-vZiU6VjW6f3zRmCKQtSIDa1zSHSDPIVKQ78_ezqmfLg69WqQsVGWDXxCjeZ-n96497BAOggkwZTPhE1THVATdjSZvrFHWSWzIXal2JWrvE8wOJWbXNvIgcy8fot6xJrxC4d_d3WMdfmmE6iMvnD72h8Vm_1jzhv4GkKRIG-TyB-AB_6DbjRSMrmHsUiRoDPi67MMbJnVqohdJai2PmGtJlgpfAG9qFXyQAWT7fX3lwhMneGSPeeIjLmZQywiVLDwJueeJHQgL0ZDeG4tWN9HepGrwPw5ItZd4tzaI2v4cP\" rel=\"nofollow noopener\" target=\"_blank\">Poster Presentation | Presented by Vasileios Kyttaris| Abstract #2273<\/a><br \/>\n        <br \/>Title: Predicting SLE Disease Activity with Blood Biomarkers: A Step Towards Precision Medicine<br \/><em>Session Title:<\/em> Poster Session C<br \/><em>Session Time:<\/em> 9:00 \u2013 11:00am PT<\/p>\n<p>\n        <strong>About\u00a0Exagen Inc.<\/strong>\n      <\/p>\n<p>Exagen is a leading provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision making with the goal of improving patients\u2019 clinical outcomes. Exagen is located in San Diego County, California.<\/p>\n<p>For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5gr2x4Z22a0BGyYzV8GcFw93h53u86m6tBk_OqDUiYgetqRLvMr-asPczhr4McG0ASVqY8nmLikmHx2KQD396I2cl9FFkvpy70hPTSxSk5TQFa9Kype19kCmQ-hVvtTUswcmahJHIP7YV8uvSgfe4OnUijjeB1a12VRQr9z4YXKwEvuZu8Jawt994T1Ugv9JPn9QUGbnSbiNqYONLIakdTxsTUmuqgcQIusxvM_7TLA=\" rel=\"nofollow noopener\" target=\"_blank\">Exagen.com<\/a>\u00a0and follow\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ts4InCDeu9ro-olXkQrW6G0V6ma0emiMTQOHOr4TixP98gPzh6KSgkb1DC-o1q8ft5KAR74vO5I_TXJA0B0WZ7RlYHl1J-B3NTltAejkdaEtVowT_HOxwohIkBRBljd_EEgS0UguJ3pRu69KxSn16JfE7AcFWGQhQeIXajmC_1xD1iQ6tTzZu2b5QiyTd0CenFuw5lBck4JslPiMlEMU-QJTHzjd0i00yI8nqn-kbl4=\" rel=\"nofollow noopener\" target=\"_blank\">@ExagenInc<\/a>\u00a0on X.<\/p>\n<p>\n        <strong>Forward Looking Statements<\/strong>\n      <\/p>\n<p>Exagen\u00a0cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen\u2019s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding our clinical research and development team\u2019s scientific abstracts for presentation at ACR Annual Conference and the potential to lead to increased adoption of any AVISE\u00ae\u00a0test.\u00a0 The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen\u2019s business, including, without limitation: delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; Exagen\u2019s commercial success depends upon attaining and maintaining significant market acceptance of its testing products among rheumatologists, patients, third-party payors and others in the medical community; Exagen\u2019s ability to successfully execute on its business strategies; third-party payors not providing coverage and adequate reimbursement for Exagen\u2019s testing products, including Exagen\u2019s ability to collect on funds due; Exagen\u2019s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen\u2019s business; and other risks described in Exagen\u2019s prior press releases and Exagen\u2019s filings with the Securities and Exchange Commission (\u201cSEC\u201d), including under the heading \u201cRisk Factors\u201d in Exagen\u2019s Annual Report on Form 10-K for the year ended December 31, 2022 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.<\/p>\n<p>\n        <strong>Investor Relations<\/strong>\n      <\/p>\n<p>Exagen Inc.<\/p>\n<p>Ryan Douglas<\/p>\n<p>\n        <u><br \/>\n          <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Sop81inJMWBkwY-HW8RT8iOje_9YFZrX3PYC6O7YPHjyvqFiUeOltouwMAyRoWCYy_cJOSzjIjDe_0PtNMpsAxevMRGfofVol8QcSmdepSs=\" rel=\"nofollow noopener\" target=\"_blank\">rdouglas@exagen.com<\/a><br \/>\n        <\/u>\n      <\/p>\n<p>760.560.1525<\/p>\n<p>\n        <strong>Company<\/strong>\n      <\/p>\n<p>Exagen Inc.<\/p>\n<p>Kamal Adawi, Chief Financial Officer<\/p>\n<p>\n        <u><br \/>\n          <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sRjFnT3lve43b49BMj32NGwZuLJOrqz-tnbpwwTuoq1J2BQS2Pk14P3GL6kmBV4fuSFoyu2VGy0vuRyc7VVj59LYV2Ejmeez0FqPoRXgwd4=\" rel=\"nofollow noopener\" target=\"_blank\">kadawi@exagen.com<\/a><br \/>\n        <\/u>\n      <\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkzMDYwNCM1ODM4NDI4IzIwMTA5NzI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OGVhZGZkODgtMzk1Ni00ZTlkLTkwZWQtNDZiYWZiNDkyZDYzLTEwMjI1NDU=\/tiny\/Exagen-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, California, Sept. 28, 2023 (GLOBE NEWSWIRE) &#8212; Exagen Inc.\u00a0(Nasdaq: XGN),\u00a0a leading provider of autoimmune testing solutions, announced today the acceptance of five abstracts at the 2023 American College of Rheumatology\u2019s (ACR) annual meeting, ACR Convergence 2023, being held November 10-15, 2023, at the San Diego Convention Center in San Diego, California. Below is the list of accepted abstracts, with links to each: Sunday, November 12, 2023 Poster Presentation | Presented by Doruk Erkan | Abstract #0099 Title: Cell-bound Complement Activation Products in Antiphospholipid Antibody-positive Patients Without Other Systemic Autoimmune DiseasesSession Title: Poster Session ASession Time: 9:00 \u2013 11:00am PT Poster Presentation | Presented by Jennifer Rogers | Abstract #0557 Title: Longitudinal Evaluation of Cell-bound Complement Activation Products in &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-786918","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, California, Sept. 28, 2023 (GLOBE NEWSWIRE) &#8212; Exagen Inc.\u00a0(Nasdaq: XGN),\u00a0a leading provider of autoimmune testing solutions, announced today the acceptance of five abstracts at the 2023 American College of Rheumatology\u2019s (ACR) annual meeting, ACR Convergence 2023, being held November 10-15, 2023, at the San Diego Convention Center in San Diego, California. Below is the list of accepted abstracts, with links to each: Sunday, November 12, 2023 Poster Presentation | Presented by Doruk Erkan | Abstract #0099 Title: Cell-bound Complement Activation Products in Antiphospholipid Antibody-positive Patients Without Other Systemic Autoimmune DiseasesSession Title: Poster Session ASession Time: 9:00 \u2013 11:00am PT Poster Presentation | Presented by Jennifer Rogers | Abstract #0557 Title: Longitudinal Evaluation of Cell-bound Complement Activation Products in &hellip; Continue reading &quot;Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-28T21:22:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkzMDYwNCM1ODM4NDI4IzIwMTA5NzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting\",\"datePublished\":\"2023-09-28T21:22:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\\\/\"},\"wordCount\":648,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkzMDYwNCM1ODM4NDI4IzIwMTA5NzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\\\/\",\"name\":\"Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkzMDYwNCM1ODM4NDI4IzIwMTA5NzI=\",\"datePublished\":\"2023-09-28T21:22:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkzMDYwNCM1ODM4NDI4IzIwMTA5NzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkzMDYwNCM1ODM4NDI4IzIwMTA5NzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting - Market Newsdesk","og_description":"SAN DIEGO, California, Sept. 28, 2023 (GLOBE NEWSWIRE) &#8212; Exagen Inc.\u00a0(Nasdaq: XGN),\u00a0a leading provider of autoimmune testing solutions, announced today the acceptance of five abstracts at the 2023 American College of Rheumatology\u2019s (ACR) annual meeting, ACR Convergence 2023, being held November 10-15, 2023, at the San Diego Convention Center in San Diego, California. Below is the list of accepted abstracts, with links to each: Sunday, November 12, 2023 Poster Presentation | Presented by Doruk Erkan | Abstract #0099 Title: Cell-bound Complement Activation Products in Antiphospholipid Antibody-positive Patients Without Other Systemic Autoimmune DiseasesSession Title: Poster Session ASession Time: 9:00 \u2013 11:00am PT Poster Presentation | Presented by Jennifer Rogers | Abstract #0557 Title: Longitudinal Evaluation of Cell-bound Complement Activation Products in &hellip; Continue reading \"Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-28T21:22:37+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkzMDYwNCM1ODM4NDI4IzIwMTA5NzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting","datePublished":"2023-09-28T21:22:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\/"},"wordCount":648,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkzMDYwNCM1ODM4NDI4IzIwMTA5NzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\/","name":"Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkzMDYwNCM1ODM4NDI4IzIwMTA5NzI=","datePublished":"2023-09-28T21:22:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkzMDYwNCM1ODM4NDI4IzIwMTA5NzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkzMDYwNCM1ODM4NDI4IzIwMTA5NzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-announces-acceptance-of-multiple-abstracts-at-acr-2023-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/786918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=786918"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/786918\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=786918"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=786918"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=786918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}